Pfizer boosts investment in Quebec-based research

Pfizer Canada has increased its investments in R&D projects managed by the Fonds de la recherche en santé du Québec (FRSQ) to $22 million. The latest investment of $5 million in the Pfizer-FRSQ-MSSS Chronic Disease Fund has produced an initial series of five projects valued at $3.5 million. The projects will be carried out by Health and Social Service Centres at Champlain and Charles LeMoyne Hospital, Chicoutimi, Laval, Rocher-Percé and Sud-Ouest Verdun. The Chronic Diseases Fund aims to evaluate and improve prevention and management initiatives by focusing on changing clinical practices for treating diabetes, cardiovascular preventive care, smoke cessation, diet and physical activity. Pfizer has also committed $17 million to the Pfizer-FRSQ Innovation Fund, which was established three years ago (R$, March 27/08)....